Shenzhen Neptunus Bioengineering Co., Ltd.

SZSE:000078 Stock Report

Market Cap: CN¥7.4b

Shenzhen Neptunus Bioengineering Past Earnings Performance

Past criteria checks 0/6

Shenzhen Neptunus Bioengineering's earnings have been declining at an average annual rate of -66.6%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been declining at an average rate of 3.5% per year.

Key information

-66.6%

Earnings growth rate

-66.9%

EPS growth rate

Healthcare Industry Growth7.0%
Revenue growth rate-3.5%
Return on equity-42.5%
Net Margin-5.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Revenues Are Not Doing Enough For Some Investors

Oct 28
Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Revenues Are Not Doing Enough For Some Investors

Here's Why Shenzhen Neptunus Bioengineering (SZSE:000078) Is Weighed Down By Its Debt Load

Jul 15
Here's Why Shenzhen Neptunus Bioengineering (SZSE:000078) Is Weighed Down By Its Debt Load

There Is A Reason Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Price Is Undemanding

Jun 07
There Is A Reason Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Price Is Undemanding

Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Share Price Is Matching Sentiment Around Its Revenues

Mar 05
Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Share Price Is Matching Sentiment Around Its Revenues

Revenue & Expenses Breakdown

How Shenzhen Neptunus Bioengineering makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:000078 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2432,331-1,7322,35043
30 Jun 2433,096-1,7322,45846
31 Mar 2434,549-1,7222,53947
31 Dec 2336,419-1,6902,74848
30 Sep 2337,520-1,0702,72948
30 Jun 2339,667-1,0532,85545
31 Mar 2338,591-1,0232,87348
01 Jan 2337,835-1,0272,86048
30 Sep 2239,234122,54428
30 Jun 2238,937672,70641
31 Mar 2240,121732,75138
01 Jan 2241,054932,78139
30 Sep 2142,053-2753,00452
30 Jun 2142,395-2762,89043
31 Mar 2142,091-2762,93443
31 Dec 2040,022-2892,75338
30 Sep 2039,535412,95750
30 Jun 2038,5081312,95338
31 Mar 2039,0131533,00939
31 Dec 1941,4932063,14042
30 Sep 1941,2603483,25644
30 Jun 1941,6812923,26148
31 Mar 1939,7233943,12655
31 Dec 1838,3814153,01245
30 Sep 1836,6086572,74761
30 Jun 1833,2697272,49670
31 Mar 1829,9546972,16050
01 Jan 1824,9406361,86850
30 Sep 1719,5936021,51117
30 Jun 1716,4685541,2830
31 Mar 1714,6674711,2040
31 Dec 1613,6064181,1650
30 Sep 1613,0653521,1340
30 Jun 1612,0815201,1070
31 Mar 1611,5724871,1310
31 Dec 1511,1184751,1140
30 Sep 1510,8093201,0900
30 Jun 1510,505261,0910
31 Mar 1510,177251,0410
31 Dec 149,802241,0400
30 Sep 149,2931139940
30 Jun 148,9221191,0150
31 Mar 148,4271199560
31 Dec 137,9931179130

Quality Earnings: 000078 is currently unprofitable.

Growing Profit Margin: 000078 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 000078 is unprofitable, and losses have increased over the past 5 years at a rate of 66.6% per year.

Accelerating Growth: Unable to compare 000078's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 000078 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-5.7%).


Return on Equity

High ROE: 000078 has a negative Return on Equity (-42.46%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies